These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 17097377

  • 21. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
    Field JJ, Fenske TS, Blinder MA.
    Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
    [Abstract] [Full Text] [Related]

  • 22. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab.
    Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA.
    Rheumatology (Oxford); 2005 Apr; 44(4):561-2. PubMed ID: 15644390
    [No Abstract] [Full Text] [Related]

  • 23. [Two children with skin rash and muscle weakness: juvenile dermatomyositis].
    Boogaard R, Drexhage VR, van Suijlekom-Smit LW.
    Ned Tijdschr Geneeskd; 2005 Jan 15; 149(3):146-50. PubMed ID: 15693592
    [Abstract] [Full Text] [Related]

  • 24. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome.
    Yassa SK, Blessios G, Marinides G, Venuto RC.
    Clin Transplant; 2005 Jun 15; 19(3):423-6. PubMed ID: 15877809
    [Abstract] [Full Text] [Related]

  • 25. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.
    J Rheumatol; 2008 May 15; 35(5):826-33. PubMed ID: 18398943
    [Abstract] [Full Text] [Related]

  • 26. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K, Prins C, Saurat JH, French LE.
    Br J Dermatol; 2006 Dec 15; 155(6):1197-200. PubMed ID: 17107389
    [Abstract] [Full Text] [Related]

  • 27. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report.
    Hennigan S, Channick RN, Silverman GJ.
    Lupus; 2008 Aug 15; 17(8):754-6. PubMed ID: 18625655
    [Abstract] [Full Text] [Related]

  • 28. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy.
    Camous L, Melander C, Vallet M, Squalli T, Knebelmann B, Noël LH, Fakhouri F.
    Am J Kidney Dis; 2008 Aug 15; 52(2):346-52. PubMed ID: 18572292
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases.
    Michel M, Habibi A, Godeau B, Bachir D, Lahary A, Galacteros F, Fifi-Mah A, Arfi S.
    Semin Arthritis Rheum; 2008 Dec 15; 38(3):228-40. PubMed ID: 18177923
    [Abstract] [Full Text] [Related]

  • 31. Multicentric reticulohistiocytosis with prominent cutaneous lesions and proximal muscle weakness masquerading as dermatomyositis.
    McIlwain KL, DiCarlo JB, Miller SB, Lim S.
    J Rheumatol; 2005 Jan 15; 32(1):193-4. PubMed ID: 15630750
    [No Abstract] [Full Text] [Related]

  • 32. Rituximab use in pediatric autoimmune diseases: four case reports.
    Polido-Pereira J, Ferreira D, Rodrigues AM, Nascimento C, Costa P, Almeida M, da Silva JE, Simão C, Stone R, Ramos F, Neto A, da Costa JC, Melo-Gomes J, Gomes-Pedro J, Viana-Queiroz M, Canhão H, Fonseca JE.
    Ann N Y Acad Sci; 2009 Sep 15; 1173():712-20. PubMed ID: 19758220
    [Abstract] [Full Text] [Related]

  • 33. Ten-year experience of juvenile dermatomyositis: a retrospective study.
    Chiu SK, Yang YH, Wang LC, Chiang BL.
    J Microbiol Immunol Infect; 2007 Feb 15; 40(1):68-73. PubMed ID: 17332910
    [Abstract] [Full Text] [Related]

  • 34. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
    Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, Nakashima H, Muta K, Abe Y, Kiyohara C, Ueda A, Nagasawa K, Yoshizawa S, Shimoda T, Harada M.
    Rheumatology (Oxford); 2008 Jun 15; 47(6):821-7. PubMed ID: 18397955
    [Abstract] [Full Text] [Related]

  • 35. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.
    Arthritis Rheum; 2007 Apr 15; 56(4):1263-72. PubMed ID: 17393458
    [Abstract] [Full Text] [Related]

  • 36. Emerging biological therapies in systemic lupus erythematosus.
    Mount GR, Gilliland WR.
    Clin Pharmacol Ther; 2008 Jan 15; 83(1):167-71. PubMed ID: 18000515
    [Abstract] [Full Text] [Related]

  • 37. Advances in the treatment of juvenile dermatomyositis.
    Stringer E, Feldman BM.
    Curr Opin Rheumatol; 2006 Sep 15; 18(5):503-6. PubMed ID: 16896290
    [Abstract] [Full Text] [Related]

  • 38. [Effects and side-effects of immunosuppressive therapy in various dermatoses (author's transl)].
    Metz G, Lurz C, Metz J.
    MMW Munch Med Wochenschr; 1974 Jul 12; 116(28):1329-38. PubMed ID: 4212641
    [No Abstract] [Full Text] [Related]

  • 39. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.
    Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA.
    Rheumatology (Oxford); 2008 Jun 12; 47(6):877-80. PubMed ID: 18403404
    [Abstract] [Full Text] [Related]

  • 40. Lymphomatoid granulomatosis in a patient with rheumatoid arthritis receiving methotrexate: successful treatment with the anti-CD20 antibody mabthera.
    Schalk E, Krogel C, Scheinpflug K, Mohren M.
    Onkologie; 2009 Jul 12; 32(7):440-1. PubMed ID: 19556825
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.